Table 1.
Baseline characteristics of 104 patients
| Variable | Number | Percent |
|---|---|---|
| Gender | ||
| Male | 36 | 34.6 |
| Female | 68 | 65.4 |
| Age (year) | ||
| ≥ 65 | 41 | 39.4 |
| < 65 | 63 | 60.6 |
| Smoking history | ||
| Former | 18 | 17.3 |
| Never | 86 | 82.7 |
| Disease stage | ||
| IIIB | 12 | 11.5 |
| IV | 92 | 88.5 |
| EGFR mutation | ||
| 19del | 46 | 44.2 |
| 21exon | 58 | 55.8 |
| Treatment Lines | ||
| First line | 38 | 36.5 |
| Second line | 66 | 63.5 |
| Oligo-metastasis before initiation TKI | ||
| Yes | 41 | 39.4 |
| No | 63 | 60.6 |
| Number of organs with metastases per patient | ||
| ≤ 3 | 53 | 51.0 |
| > 3 | 51 | 49.0 |
| Central nervous system metastasis | ||
| Yes | 44 | 42.3 |
| No | 60 | 57.7 |
| Surgery | ||
| Yes | 23 | 22.1 |
| No | 81 | 77.9 |
| Distribution of metastases before TKI initiation | ||
| Lymph nodes | 77 | 74.0 |
| Lung | 57 | 54.8 |
| Bone | 55 | 52.9 |
| Brain | 43 | 41.3 |
| Pleura | 14 | 13.5 |
| Liver | 9 | 8.7 |
| Others | 40 | 38.5 |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.